Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib Adjuvant Therapy in Stage I ALK-positive NSCLC
NCT06772610Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2029
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06772610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772610.